Accelerating cancer research through comprehensive genomic analysis

Overview

Cancer is a challenging multifactorial disease and the rapid advancement of sequencing technologies over the last two decades has revealed unprecedented insights into the genomic causes and implications of cancer. However, a vast proportion of cancers cannot be explained by simple point mutations detected using legacy short-read sequencing technologies. In this white paper, discover how nanopore sequencing technology provides extensive analyses of structural variants, repeat regions, DNA/RNA methylation, cell-free and circulating tumour DNA (cfDNA and ctDNA), fusion genes and full-length transcript isoforms to truly understand cancer biology.

In this white paper, you will:

• Learn the importance of cancer research and its recent developments
• Discover the limitations of legacy sequencing technologies
• Find out how nanopore sequencing overcomes these limitations
• Read real-world case studies of how researchers are utilising nanopore sequencing to deliver new insights into a wide range of cancers, including cervical cancer, colorectal cancer, acute myeloid leukaemia, and organoids